臨床泌尿器科76巻6号

2022年05月発行

特集 ここまで来た! 腎盂・尿管癌診療―エキスパートが語る臨床の最前線

〈治療編〉

がん化学療法後に増悪した転移性腎盂・尿管癌に対するエンホルツマブ ベドチン治療の最前線

著者： 藤田和利¹ 南高文¹ 植村天受¹

所属機関： ¹近畿大学医学部泌尿器科学教室

ページ範囲：P.410 - P.414

文献概要

▶ポイント

・がん化学療法後に増悪した転移性腎盂・尿管癌に対してエンホルツマブ ベドチンにより予後を改善する．

・腎機能低下症例に対してもエンホルツマブ ベドチンは投与可能である．

・Nectin-4の陽性率は膀胱癌と比べ，腎盂・尿管癌では低い可能性がある．

参考文献

1） Rouprêt M, et al : European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma : 2017 Update. Eur Urol 73 : 111-122, 2018

2） Heath EI, et al : The Biology and Rationale of Targeting Nectin-4 in Urothelial Carcinoma. Nat Rev Urol 18 : 93-103, 2021

3） Fabre-Lafay S, et al : Nectin-4 Is a New Histological and Serological Tumor Associated Marker for Breast Cancer. BMC Cancer 7 : 73, 2007

4） Derycke MS, et al : Nectin 4 Overexpression in Ovarian Cancer Tissues and Serum : Potential Role as a Serum Biomarker. Am J Clin Pathol 134 : 835-845, 2010

5） Nishiwada S, et al : Nectin-4 Expression Contributes to Tumor Proliferation, Angiogenesis and Patient Prognosis in Human Pancreatic Cancer. J Exp Clin Cancer Res 34 : 30, 2015

6） Tomiyama E, et al : Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma. Int J Mol Sci 21 : 5390, 2020

7） Zhang Y, et al : A Novel PI3K/AKT Signaling Axis Mediates Nectin-4-Induced Gallbladder Cancer Cell Proliferation, Metastasis and Tumor Growth. Cancer Lett 375 : 179-189, 2016

8） Heath EI, et al : The Biology and Rationale of Targeting Nectin-4 in Urothelial Carcinoma. Nat Rev Urol 18 : 93-103, 2021

9） Rosenberg JE, et al : Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol 37 : 2592-2600, 2019

10） Powles T, et al : Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 384 : 1125-1135, 2021

11） Yu EY, et al : Enfortumab Vedotin After PD-1 or PD-L1 Inhibitors in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma （EV-201） : A Multicentre, Single-Arm, Phase 2 Trial. Lancet Oncol 22 : 872-882, 2021

12） Challita-Eid PM, et al : Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res 76 : 3003-3013, 2016

13） Tagawa ST, et al : TROPHY-U-01 : A Phase II Open-Label Study of Sacituzumab Govitecan in Patients with Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol 39 : 2474-2485, 2021

14） Ungaro A, et al : Antibody-Drug Conjugates in Urothelial Carcinoma : A New Therapeutic Opportunity Moves from Bench to Bedside. Cells 11 : 803, 2022

15） Faraj SF, et al : Assessment of Tumoral PD-L1 Expression and Intratumoral CD8＋T Cells in Urothelial Carcinoma. Urology 85 : 703.e1-6, 2015

16） Kobayashi G, et al : Clinicopathological Significance of Claspin Overexpression and Its Efficacy as a Novel Biomarker for the Diagnosis of Urothelial Carcinoma. Virchows Arch 480 : 621-633, 2021

17） Zaman S, et al : Targeting Trop-2 in Solid Tumors : Future Prospects. Onco Targets Ther 12 : 1781-1790, 2019

18） Rodriguez Pena MDC, et al : Immunohistochemical Assessment of Basal and Luminal Markers in Non-Muscle Invasive Urothelial Carcinoma of Bladder. Virchows Arch 475 : 349-356, 2019